erlotinib + gemcitabine + nab-paclitaxel
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Pancreatic Cancer
Conditions
Advanced Pancreatic Cancer
Trial Timeline
Feb 3, 2010 → Jan 25, 2012
NCT ID
NCT01010945About erlotinib + gemcitabine + nab-paclitaxel
erlotinib + gemcitabine + nab-paclitaxel is a phase 1 stage product being developed by Astellas Pharma for Advanced Pancreatic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01010945. Target conditions include Advanced Pancreatic Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01010945 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Pancreatic Cancer